Top HHS research and development in biotechnology (except nanobiotechnology) contractors
In the 12 months ending Oct 5, 2026, the Department of Health and Human Services obligated $1.7B in net prime contract dollars under NAICS 541714, up 67.9% from $1.0B in the preceding 12 months. 207 prime contractors received positive obligations, and 21 of them accounted for 80% of that spend.
Prime contracts funded by the Department of Health and Human Services. Latest 12 months: Oct 6, 2025 to Oct 5, 2026. Source: USAspending.gov.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year (October to September).
Top HHS contractors for NAICS 541714
Ranked by positive obligations in the latest 12 months. Share is of all positive obligations in this market.
| # | Contractor | Latest 12 mo | Prior 12 mo | Share | Rank change |
|---|---|---|---|---|---|
| 1 | Albert B. Sabin Vaccine Institute, Inc. (the) | $266.2M | $70.4M | 15.3% | ▲ 2 |
| 2 | Shionogi Inc | $156.1M | $0 | 9.0% | New |
| 3 | Advanced Technology International | $154.0M | −$200.6M | 8.8% | New |
| 4 | Amgen USA Inc | $126.0M | $89.9M | 7.2% | ▼ 2 |
| 5 | Kaleo, Inc. | $99.8M | $26.0M | 5.7% | ▲ 8 |
| 6 | start2 Group, Inc. | $89.1M | $105.2M | 5.1% | ▼ 5 |
| 7 | Mapp Biopharmaceutical, Inc. | $83.1M | $50.0M | 4.8% | — |
| 8 | Basilea Pharmaceutica International Ltd, Allschwil | $54.9M | $63.8M | 3.1% | ▼ 4 |
| 9 | Ossium Health, Inc. | $48.9M | $0 | 2.8% | New |
| 10 | PPD Development LP | $40.1M | $3.6M | 2.3% | ▲ 51 |
| 11 | Vericel Corporation | $34.9M | $0 | 2.0% | New |
| 12 | Public Health Vaccines LLC | $33.5M | $19.5M | 1.9% | ▲ 7 |
| 13 | Cerus Corporation | $33.2M | $0 | 1.9% | New |
| 14 | Spectral MD, Inc. | $31.7M | $0 | 1.8% | New |
| 15 | 4j Therapeutics Inc | $25.5M | $17.0M | 1.5% | ▲ 9 |
What changed in the last 12 months
Contractors with the largest change in reported obligations versus the preceding 12 months.
Largest gains
- Advanced Technology International−$200.6M → $154.0M (+$354.6M) · now #3
- Albert B. Sabin Vaccine Institute, Inc. (the)$70.4M → $266.2M (+$195.8M) · now #1
- Shionogi Inc$0 → $156.1M (+$156.1M) · now #2
Largest declines
- Cidara Therapeutics Inc$58.1M → $0 (−$58.1M) · no latest-period obligations
- Siga Technologies, Inc.$53.1M → $2.1M (−$51.1M) · now #71
- University Lab Partners$19.1M → −$17.5M (−$36.6M) · no latest-period obligations
New to this market
44 contractors received their first obligations in this market (since FY2022) during the latest 12 months. The largest:
| Contractor | First obligation | Latest 12 mo |
|---|---|---|
| Shionogi Inc | Apr 6, 2026 | $156.1M |
| Vericel Corporation | Apr 1, 2026 | $34.9M |
| Oxos Medical Inc | Sep 25, 2026 | $9.6M |
| Rutgers the State University of New Jersey | Sep 24, 2026 | $6.5M |
| Tranquil Clinical and Research Consulting Services LLC | Sep 21, 2026 | $4.1M |
| Physical Sciences Inc. | Feb 26, 2026 | $3.5M |
| The Research Foundation for the State University of New York | Dec 3, 2025 | $2.9M |
| Optosurgical, LLC | Apr 8, 2026 | $2.1M |
Where the money comes from
Funding sub-agencies within the Department of Health and Human Services, latest 12 months. The funding organization can differ from the office that runs the requirement.
| Funding sub-agency | Latest 12 mo | Prior 12 mo | Change |
|---|---|---|---|
| Office of Assistant Secretary for Preparedness and Response | $1.4B | $766.8M | Up $620.6M (80.9%) |
| National Institutes of Health | $250.3M | $205.5M | Up $44.8M (21.8%) |
| Food and Drug Administration | $40.9M | $26.1M | Up $14.9M (57.1%) |
| Centers for Disease Control and Prevention | $7.3M | $5.8M | Up $1.4M (24.1%) |
| Indian Health Service | $215K | $152K | Up $63K (41.5%) |
Potential recompetes
Large awards in this market whose current period of performance ends in the next 18 months. Treat these as research leads: options, extensions, and follow-on vehicles often change the timing.
| Award | Incumbent | Obligated | Current end |
|---|---|---|---|
| 75A50120C00169 | Locus Biosciences Inc CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG… | $62.9M | Dec 31, 2026 |
| 75N93024F00001 | PPD Development LP NIAID CLINICAL SITE MONITORING (NCSM) | $73.2M | Jan 31, 2027 |
| 75N93024F00001 | Technical Resources International, Inc. NIAID/DAIDS REGULATORY SUPPORT CENTER | $56.6M | Apr 14, 2027 |
| 75A50124F61006 | Advanced Technology International OT TASK ORDER 6 - DXR2 | $100.0M | Jun 16, 2027 |
| 75A50120C00177 | Vedanta Biosciences, Inc. TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. | $68.0M | Aug 31, 2027 |
| 75A50125C00017 | Cidara Therapeutics Inc DEVELOPMENT OF CD388 AS A LONG-LASTING PROPHYLACTIC ANTI-VIRAL OPTION FOR PROTECTION AGAINST THE HEALTH IMPACTS CAUSED BY INFLUENZA | $58.1M | Sep 29, 2027 |
| 75N93019C00070 | Seattle Children's Hospital IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) | $52.0M | Sep 29, 2027 |
| 75A50119C00055 | Albert B. Sabin Vaccine Institute, Inc. (the) THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $70.3M | Sep 30, 2027 |
| 75A50123F61005 | Advanced Technology International OT TASK ORDER 5 | $161.1M | Dec 31, 2027 |
| 75A50123C00056 | Modex Therapeutics, Inc ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND SEASONAL AND HIGHLY PATHOGENIC AVIAN INFLUENZA. | $103.5M | Feb 29, 2028 |
Common questions
Who are the top HHS contractors for NAICS 541714?
In the latest 12 months, Albert B. Sabin Vaccine Institute, Inc. (the) ($266.2M), Shionogi Inc ($156.1M), Advanced Technology International ($154.0M) received the most HHS obligations for research and development in biotechnology (except nanobiotechnology).
How concentrated is this market?
The eight largest primes held 59.1% of positive obligations, and Albert B. Sabin Vaccine Institute, Inc. (the) alone held 15.3%. 44 contractors won their first obligations in this market during the latest 12 months.
Are any large HHS NAICS 541714 contracts ending soon?
10 of the largest awards in this market reach their current end date in the next 18 months. The first is 75A50120C00169 (Locus Biosciences Inc, $62.9M obligated), ending Dec 31, 2026. An end date is a research lead, not a confirmed recompete: options and extensions often move it.
Related markets
NAICS 541714 across all agencies
DoD · NAICS 541714
$340.7MVA · NAICS 541714
$33.5MNASA · NAICS 541714
$22.3MFigures are net obligations on prime contracts (award types A–D) from USAspending.gov, grouped by funding agency and the NAICS code on each award. Net obligations include deobligations and corrections, so they can differ from positive-obligation totals. See methodology.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.